Stock Analiz

Neogenomics Inc. (NEO) stock forecast and price target

Price $16.02 · data as of November 13, 2026

12-month price target

Average target$23.40
Upside / downside+46.1%
Analysts10
ConsensusNone
Low $19.00Average $23.40High $35.00

Gold marker: average target · white marker: today’s price ($16.02)

Analyst ratings

Strong buy 2Buy 6Hold 3Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$0.20+70.0%$808M
Next fiscal year
ends December 31, 2027
$0.31+54.2%$887M
Next quarter
ends December 31, 2026
$0.06+7.6%$211M
Quarter after
ends March 31, 2027
$0.05+440.0%$206M

Consensus of the analysts covering Neogenomics, updated daily. In the last 30 days 9 estimates were raised and 0 lowered.

Our model vs. Wall Street

Analysts see 46.1% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Neogenomics’s intrinsic value about 84% below today’s market value, and it scores 0.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Neogenomics stock price target?

The average 12-month target from 10 analysts is $23.40, 46.1% above the current price of $16.02 Targets range from $19.00 to $35.00.

Is Neogenomics a buy according to analysts?

The consensus rating is “None” (2 strong buy, 6 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is Neogenomics expected to earn?

Analysts expect EPS of $0.20 for the fiscal year ending December 31, 2026 and $0.31 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.